US Equity Holdings

Chester Aldridge, the firm's Founder, Chairman, and CEO, drives all investment and operational decisions. The leadership team also includes CFO Ben Zadik and Chief of Staff Tony Shapiro. Aldridge's approach relies on his deep operating background — he structures, finances, and often actively manages the portfolio companies rather than delegating to external managers.

It operates as a hybrid holding company and advisory platform. While it incubates and finances companies reminiscent of a venture studio, it does not raise external LP funds for a blind pool. Aldridge uses his own capital and his role as a strategic advisor to a large Canadian family office to pursue principal investments, often retaining operational control.

The firm is stage-agnostic but frequently engages at concept and seed stages, particularly in hard-tech and biotech where it can shape intellectual property from inception. It has also participated in later-stage commercial rounds, such as the $39.9 million financing for Credence MedSystems, and retains long-term advisory positions in companies moving toward pilot manufacturing.

Aldridge sources opportunities through his personal network of IP portfolios, research institutions such as Fraunhofer, NASA, and the Buck Institute, and his relationships with serial entrepreneurs and family offices. The firm often creates deals by licensing foundational technology and then assembling a management team to commercialize it.

Chester Aldridge serves as a strategic advisor and partner to one of Canada's largest family offices, per the firm's website. In that capacity, he guides investment strategy, evaluates opportunities, and executes across private equity, real estate, and alternative assets. The relationship is advisory, not a consolidation of the two entities' balance sheets, but it can create co-investment pathways.

The firm's wealth origin is not publicly disclosed. Aldridge's capital appears to stem from multiple serial-entrepreneur exits across video-game publishing, music management, internet services, and intellectual-property licensing, rather than a single inherited or industrial fortune.

Based on public disclosures, the firm operates almost exclusively through direct investments, incubations, and IP licensing. There is no evidence that it acts as a limited partner in external venture or private equity funds. Its capital forms the core of startup balance sheets, and it sometimes syndicates strategic corporate investors like Novartis or Molex into portfolio companies.